Exelixis

YTD

ALL

Trade Exelixis 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About EXEL

Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic.

CEO

Michael M. Morrissey

CEOMichael M. Morrissey

Employees

1,147

Employees1,147

Headquarters

Alameda, California

HeadquartersAlameda, California

Founded

1994

Founded1994

Employees

1,147

Employees1,147

EXEL Key Statistics

Market cap

11.79B

Market cap11.79B

Price-Earnings ratio

18.48

Price-Earnings ratio18.48

Dividend yield

—

Dividend yield—

Average volume

2.79M

Average volume2.79M

High today

$44.20

High today$44.20

Low today

$43.45

Low today$43.45

Open price

$43.95

Open price$43.95

Volume

2.18M

Volume2.18M

52 Week high

$49.62

52 Week high$49.62

52 Week low

$32.38

52 Week low$32.38

Stock Snapshot

The current Exelixis(EXEL) stock price is $43.94, with a market capitalization of 11.79B. The stock trades at a price-to-earnings (P/E) ratio of 18.48.

On 2026-02-10, Exelixis(EXEL) stock moved within a range of $43.45 to $44.20. With shares now at $43.94, the stock is trading +1.1% above its intraday low and -0.6% below the session's peak.

Trading activity shows a volume of 2.18M, compared to an average daily volume of 2.79M.

Over the past 52 weeks, Exelixis(EXEL) stock has traded between a high of $49.62 and a low of $32.38.

EXEL News

Simply Wall St 2d

Exelixis Is Up 6.1% After FDA Accepts Colorectal Cancer Combo NDA - What's Changed

In early February 2026, Exelixis, Inc. reported that the FDA accepted its New Drug Application for zanzalintinib plus atezolizumab to treat previously treated a...

Simply Wall St 3d

FDA NDA Move Puts Exelixis Colorectal Cancer Bet To The Test

FDA accepts Exelixis' New Drug Application for zanzalintinib plus atezolizumab in metastatic colorectal cancer. The application is based on pivotal trial data...

TipRanks 6d

Exelixis price target raised to $44 from $41 at Barclays

Barclays analyst Etzer Darout raised the firm’s price target on Exelixis (EXEL) to $44 from $41 and keeps an Equal Weight rating on the shares as part of a Q4 e...

Analyst ratings

50%

of 22 ratings

Buy

45.5%

Hold

50%

Sell

4.5%

More EXEL News

Simply Wall St 6d

Assessing Exelixis Valuation After FDA Accepts Zanzalintinib NDA In Metastatic Colorectal Cancer

Exelixis (EXEL) is back in focus after the U.S. Food and Drug Administration accepted its New Drug Application for zanzalintinib plus atezolizumab in previously...

TipRanks 7d

Exelixis: Advancing Zanzalintinib Pipeline Underpins Buy Rating and $52 Target on Multi-Tumor Commercial Potential

H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Exelixis today and set a price target of $52.00. Claim 50% Off TipRanks Premium Unlock hedge fun...

People also own

Based on the portfolios of people who own EXEL. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.